How did OPKO Health's revenue and expenses trend in Q4 2024?

OPKO Health's revenue and expenses in Q4 2024 showed a business-oriented revenue structure with diagnostics and pharmaceutical segments contributing significantly. Here's a detailed analysis:

1. Revenue Trend:
   • The company's total revenue for Q4 2024 was $480.67 million.
   • The revenue was distributed across various segments, including diagnostics, pharmaceuticals, services, products, and intellectual property transfers.
   • The most significant contributors were the diagnostics segment with $102.84 million and the pharmaceutical segment with $151.95 million.
   • The services segment also contributed $102.8 million, while the products and intellectual property transfer segments accounted for $34.8 million and $12.3 million, respectively.
2. Expense Trend:
   • Total expenses for the period were $183.6 million.
   • The company's expense structure did not significantly differ from its revenue segments, indicating a balanced cost allocation.
   • The highest expenses were related to the pharmaceutical segment, followed by diagnostics and services.
3. Net Income:
   • OPKO Health reported a net income of $14 million for Q4 2024.
   • This indicates a healthy profitability margin for the period, considering the total revenue and expenses.

In conclusion, OPKO Health demonstrated a robust revenue model with strong contributions from various segments, while managing expenses effectively to achieve a positive net income. This trend suggests a stable financial performance for the company during Q4 2024.